Novo Nordisk A/S (NVO)

Market Cap	167.25B -54.2%
Revenue (ttm)	48.59B +6.4%
Net Income	16.10B +1.4%
EPS	3.62 +1.8%
Shares Out	4.44B
PE Ratio	10.39
Forward PE	11.35
Dividend	$1.23 (3.29%)
Ex-Dividend Date	Aug 18, 2025

Volume	24,221,636
Open	37.54
Previous Close	37.62
Day's Range	37.33 - 37.86
52-Week Range	37.31 - 91.90
Beta	0.40
Analysts	Hold
Price Target	54.25 (+44.86%)
Earnings Date	Feb 4, 2026

About NVO

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 69,505
• Stock Exchange: NYSE
• Ticker Symbol: NVO
• Website: https://www.novonordisk.com

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK

Analyst Summary

According to 11 analysts, the average rating for NVO stock is "Hold." The 12-month stock price target is $54.25, which is an increase of 44.86% from the latest price.

Price Target

$54.25

(44.86% upside)

Analyst Consensus: Hold